Glaukos Corporation: Investor Presentation Highlights – March 2026

Overview

Glaukos Corporation’s latest investor presentation outlines robust growth, a pipeline of innovative therapies, and key developments in chronic eye disease care. The company is positioning itself as a best-in-class growth entity with a diversified, industry-leading pipeline focused on unmet clinical needs in glaucoma, keratoconus, blepharitis, myopia, and retinal diseases.

Key Highlights

• Exceptional Growth Metrics: Glaukos reported 30% topline growth in 2025 and a 20% ten-year revenue CAGR. Over \$800 million has been invested in R&D since 2018, underscoring commitment to innovation.
• Industry-Leading Pipeline: Glaukos currently has 13 disclosed pipeline programs and 12 commercialized products targeting major ophthalmic conditions. These include ocular hypertension, open-angle glaucoma, keratoconus, blepharitis, myopia, age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
• Addressing Two Major Unmet Clinical Needs:
  • Interventional Glaucoma (IG): Glaukos is pioneering a shift from the conventional “drops first” paradigm to procedural pharmaceuticals. Their iDose TR therapy anchors securely in scleral tissue, delivering long-duration drug therapy (up to three years) directly to the anterior chamber. It is the first and only FDA-approved glaucoma procedural pharmaceutical, with approval for repeat administration (January 2026). Recent Phase 3 data shows non-inferiority to topical timolol, and 81% of subjects were free of IOP-lowering topical meds at 12 months.
  • Interventional Keratoconus: Keratoconus remains vastly underdiagnosed and undertreated. Glaukos’s Epioxa is the first FDA-approved “epithelium-on” treatment (incision-free, topical drug therapy catalyzed by oxygen and light) for keratoconus, offering a streamlined procedure and faster recovery. Epioxa launches in Q1 2026, supported by new infrastructure including patient service hubs, payer coverage, and specialty pharma support.
• Product Roadmap & Pipeline Depth:
  • iDose Platform: Advancing next-generation products like iDose TRIO (Phase 3b) and iDose TREX (Phase 2b/3), designed for potentially longer drug duration and in-office administration.
  • iStent Technologies: 14 years of commercial leadership with over 300 peer-reviewed publications. iStent infinite, launched for advanced glaucoma, provides up to 240° of powerful outflow coverage.
  • Keratoconus Pipeline: Photrexa (Epi-off, FDA-approved 2016), Epioxa (Epi-on, FDA-approved 2025), third-generation iLink (Phase 2, customized spherical therapy), and iVeena (Phase 2).
  • Blepharitis & Myopia: Novel eyelid drug delivery platform (iLution), with a lead candidate in Phase 2 for demodex blepharitis. Estimated market size for blepharitis is \$400+ million in 2025, affecting 25 million people in the US.
  • Retina XR Platform: Biodegradable implants for AMD, DME, and RVO. Phase 2a clinical trial enrollment is complete for IVT multi-kinase inhibitor. Retinal disease affects 28+ million people in the US, with a \$10 billion market.
• Financial Strength & Infrastructure:
  • 2025 net sales reached \$507 million; 2026 forecast is \$610 million.
  • Gross margin in Q4 2025 was 85% (non-GAAP).
  • Healthy balance sheet with \$283 million in cash/equivalents and no debt (as of 12/31/2025).
  • Global infrastructure: direct operations in 17 countries, 300+ commercial personnel.
  • Specialized manufacturing expertise with a new facility in Huntsville, AL.
• Pipeline Milestones & Launch Timings:
  • Epioxa launches in Q1 2026 with planned expansion of patient services, payer coverage, advocacy, and increased marketing spend throughout the year.
  • iDose TR and its future variants (TRIO, TREX) are advancing through clinical stages, with potential to revolutionize glaucoma therapy and practice efficiency.

Potential Price-Sensitive & Shareholder-Relevant Information

• FDA Approvals: Recent FDA approval for repeat administration of iDose TR (January 2026) and Epioxa (December 2025) could significantly expand market potential and drive revenue growth.
• Clinical Trial Success: New Phase 3 analysis demonstrates non-inferiority of iDose TR to topical timolol at three years, supporting strong adoption by healthcare providers.
• Product Launches: Epioxa’s commercial launch in Q1 2026 and the advancing pipeline of next-generation therapies (iDose TRIO, TREX, third-generation iLink for KC) are pivotal events.
• Market Opportunity: Glaukos is targeting large and underserved patient populations with innovative, compliance-independent therapies. The company projects that by 2035, US ophthalmologists could be performing as many interventional glaucoma procedures as cataract surgeries, signaling huge market expansion.
• Financial Performance: Sustained revenue growth, high margins, and a debt-free balance sheet provide stability and capacity for future investments.
• Practice Efficiency: IG therapies offer practice efficiency for ophthalmic surgeons, especially amid continued cataract surgery fee reductions, which could accelerate adoption.
• Emergence of New Specialists: Vision for a new breed of IG specialists conducting primarily injection therapies, expanding the company’s addressable market.
• Rare Disease Infrastructure: Investment in rare disease patient education, advocacy, and specialty pharma support is set to improve patient access and drive adoption of Epioxa and future keratoconus therapies.
• Potential New Standards of Care: Customized, spherical therapy for keratoconus (currently in Phase 2) could further disrupt the market and drive long-term growth.

Risks & Forward-Looking Statements

• Commercial success depends on successful commercialization of new therapies (iDose TR, Epioxa), payer coverage, and acceptance by healthcare providers.
• Risks include supply chain dependencies, manufacturing disruptions, regulatory hurdles, and potential recalls or safety issues.
• Healthcare legislative changes, trade policy shifts, cybersecurity threats, and intellectual property litigation could materially affect operations.

Conclusion

Glaukos Corporation’s March 2026 investor presentation reveals multiple catalysts for future growth, including new FDA approvals, product launches, clinical trial successes, and continued innovation in chronic eye disease management. The company’s financial strength, global infrastructure, and industry-leading pipeline position it as a compelling opportunity for investors seeking exposure to disruptive healthcare technologies in ophthalmology. Shareholders should closely monitor upcoming launches and clinical milestones, which may prove to be significant share price movers.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All statements regarding future performance are forward-looking and subject to risks and uncertainties. Investors should review Glaukos Corporation’s filings with the SEC for further details.

View GLAUKOS Corp Historical chart here